How immune cells recognize cancer, and how tumors hide from them
Cancer cells deploy a molecular trick to conceal themselves from the immune system. New research reveals how tumors recycle two specific proteins through their internal transport network, causing T cells, the immune system's hunters, to lose contact.
When a T cell attacks a cancer cell, nothing about it is random. It requires a precise molecular contact point: the immune synapse, a temporary but highly organized junction between the T cell and the cancer cell. Through that synapse, signals are exchanged that activate the T cell to kill. But tumors are evolutionarily resourceful, and they have found ways to disrupt that synapse.
A study published in eLife describes how cancer cells use a specific protein transport system, clathrin-independent endocytosis driven by the protein EndoA3, to pull two molecules off the cell surface that are critical for the immune synapse: ICAM-1 and ALCAM. Endocytosis is the process by which a cell takes up molecules from its outer wall and shuttles them inward. In this case, those two proteins are not simply broken down; instead, they are ferried back to an internal depot, the trans-Golgi network, from which they can be strategically redistributed.
Recycling as a survival strategy
What makes this mechanism remarkable is its sophisticated logistics. The cancer cell does not permanently remove ICAM-1 and ALCAM; it actively manages their presence on the cell surface. By temporarily pulling them away at the moment a T cell approaches, the tumor reduces the chances of effective recognition and attack. This is not passive invisibility, it is active immunological sabotage.
The finding matters for our understanding of immunotherapy, treatments that harness your own immune system to fight cancer. Checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 have transformed oncology over the past decade, yet a substantial proportion of patients do not respond to them. Some of that resistance may be explained by mechanisms like the one described here: the tumor disrupts the physical interaction with the T cell before inhibitory signals even come into play.
A new target for therapy?
If EndoA3 is the key protein driving this transport system, it is a potential therapeutic target. Blocking EndoA3 could keep ICAM-1 and ALCAM on the cell surface for longer, allow the immune synapse to form more effectively, and let T cells attack with greater force. Whether that works in practice without unwanted side effects is a question for preclinical and clinical studies, none of which have been done yet.
The research illustrates a broader pattern in cancer immunology: the more precisely you understand the molecular conversation between the immune system and a tumor, the more potential points of intervention you uncover. But also the more complex the puzzle turns out to be.